Merck Sees $1.5M in Bullish Call Activity as Stock Sits Near 52-Week Highs

By TrendSpider Editor

Two unusual call contracts totaling $1,525,617 in premium hit the tape for Merck & Company, Inc. on Wednesday, both targeting the $155 strike with expirations in September and December 2026. MRK shares are trading at $153.39, down 1.95% on the session, yet remain well above the 52-week low of $77.58

Merck Sees $1.5M in Bullish Call Activity as Stock Sits Near 52-Week Highs

Two unusual call contracts totaling $1,525,617 in premium hit the tape for Merck & Company, Inc. on Wednesday, both targeting the $155 strike with expirations in September and December 2026. MRK shares are trading at $153.39, down 1.95% on the session, yet remain well above the 52-week low of $77.58 and are approaching the 52-week high of $156.92. The clustering of call activity at a strike just above current levels suggests traders are positioning for a near-term breakout attempt.

Key Drivers of the MRK Stock Move

• Main Catalyst: Two out-of-the-money call contracts at the $155 strike were flagged as unusual, with a combined premium of $1,525,617. The September 4 contract printed 1,426 contracts at 735% of open interest, while the December 18 contract saw 1,000 contracts at 45% of open interest.
• Bull Case: The September 4 call, expiring in just over a week, printed at 735% of its open interest, a signal that fresh, aggressive positioning is entering the market rather than a roll or hedge. The December 18 call adds $1,155,000 in premium behind the same $155 strike, reinforcing conviction in a move above that level over the medium term.
• Bear Case: MRK is down 1.95% on the session even as this bullish flow arrives, suggesting the broader tape is not confirming the options activity. With the $155 strike sitting above the current price of $153.39, both contracts expire worthless if shares fail to recover and push through that resistance level.

The forward setup for MRK is notable given how close the stock sits to its 52-week high of $156.92. A sustained move through $155 would put MRK in position to challenge and potentially set fresh annual highs. The short-dated September 4 expiration means the market will get a quick verdict on whether this positioning was well-timed. The December expiration gives the longer-dated trade more runway to develop and may be reflecting expectations around a scheduled catalyst, such as a data readout or investor event, in the months ahead. The combination of a near-term and longer-dated trade at the same strike is a pattern often associated with traders who see a defined upside level as meaningful resistance they expect to eventually break.

MRK Unusual Options Activity

• Contract 1: Call, $155 strike, expiring September 4, 2026 | Volume: 1,426 | Open Interest: 735% | Out of the money | Premium: $370,617
• Contract 2: Call, $155 strike, expiring December 18, 2026 | Volume: 1,000 | Open Interest: 45% | Out of the money | Premium: $1,155,000

MRK Seasonality

Late August and early September have historically been a mixed-to-challenging period for large-cap pharmaceutical names as broader market seasonality tends to weaken into the end of summer. However, accumulation of call premium ahead of potential fall catalysts, such as medical conferences and FDA decision windows, is a pattern that has historically preceded significant moves in drug company stocks.

MRK Relative Performance

MRK is off 1.95% on Wednesday's session, which represents modest underperformance relative to the broader market on the day. However, the stock's position near the top of its 52-week range of $77.58 to $156.92 reflects substantial longer-term strength. At $153.39, MRK is trading within roughly 2% of its annual high, indicating that despite today's pullback, the stock has been one of the stronger performers in the large-cap pharmaceutical space over the past year.